H.C. Wainwright raised the firm’s price target on Brainsway (BWAY) to $18 from $17 and keeps a Buy rating on the shares. The firm notes BrainsWay announced that the FDA had granted a label expansion for its deep transcranial magnetic stimulation system. Expanded FDA clearance makes Deep TMS available as an adjunct therapy for adolescents aged 15-21 with major depressive disorder. Wainwright notes this was achieved a scant two months after the FDA granted expanded clearance to include an accelerated treatment protocol for MDD and patients with comorbid anxiety symptoms.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BWAY:
- BrainsWay Gains FDA Approval for Adolescent Depression Treatment
- Brainsway’s Deep TMS device granted FDA clearance in Major Depressive Disorder
- BrainsWay’s Q3 2025 Earnings Call Highlights Growth
- Brainsway price target raised to $23 from $19 at Northland
- Brainsway price target raised to $19 from $18.60 at Ladenburg